TARRYTOWN, N.Y.--(BUSINESS WIRE)--Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) today announced that it has been selected to present results from a phase 1b clinical trial of PRO 140, an investigational drug for the treatment of HIV/AIDS, at the 4th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention in Sydney, Australia. The oral presentation, entitled, “Antiviral Effects and Tolerability of the CCR5 Monoclonal Antibody PRO 140: A Proof-of-Concept Study in HIV-Infected Individuals,” is scheduled to take place on July 25, 2007 at 4:30 p.m., Australian Eastern Standard Time (2:30 a.m., U.S. Eastern Daylight Time). The Company also plans to provide an update to its PRO 140 development program in the presentation. A separate poster presentation at the IAS conference will assess PRO 140’s in vitro activity against virus that is resistant to approved classes of HIV drugs.
